文献速递神经技术与安全PETMR

使用18F-DPA-714 PET/MRI进行小胶质细胞活化显像以检测自身免疫性脑炎

Microglial Activation Imaging Using 18F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis.
PubMed 文献 · Radiology · 2024-01-01

这项前瞻性研究纳入25例自身免疫性脑炎患者和10名健康对照,比较18F-DPA-714 PET与常规MRI的阳性检出率(72% vs 44%,P=0.065,差异未达统计学显著)。发生癫痫发作的患者全皮质平均SUVR显著高于无癫痫发作者(1.23±0.21 vs 1.15±0.18,P=0.003)。13例随访患者中11例(85%)在免疫抑制治疗后摄取降低并伴症状缓解。

要点

  • 18F-DPA-714 PET对自身免疫性脑炎的阳性检出率为72%(18/25),常规MRI为44%(11/25),两者差异未达统计学显著(P=0.065)。
  • 有癫痫发作的自身免疫性脑炎患者全皮质平均SUVR显著高于无癫痫发作者(1.23±0.21 vs 1.15±0.18,P=0.003)。
  • 13例随访患者中11例(85%)免疫抑制治疗后18F-DPA-714摄取降低并伴症状缓解。

核心结论

  • 18F-DPA-714 PET在补充MRI检测自身免疫性脑炎方面具有潜在价值。

研究设计与样本

  • 前瞻性研究,纳入25例自身免疫性脑炎患者(平均年龄39.24岁±19.03)和10名健康对照(平均年龄28.70岁±5.14),于2021年12月至2023年4月入组,所有参与者接受脑18F-DPA-714 PET/MRI及抗体检测。

关键影像表现/征象

  • 阳性发现定义为相应脑区内18F-DPA-714摄取强度超过健康对照平均标准化摄取值比(SUVR)加2个标准差这一阈值。
  • 有癫痫发作的自身免疫性脑炎患者全皮质平均SUVR为1.23±0.21,无癫痫发作者为1.15±0.18,前者显著高于后者(P=0.003)。
  • 13例随访患者中11例(85%)在免疫抑制治疗后18F-DPA-714摄取降低并伴症状缓解。

诊断标准与关键数值

  • 18F-DPA-714 PET对自身免疫性脑炎的阳性检出率为72%(18/25),常规MRI为44%(11/25),差异未达统计学显著(P=0.065)。
  • 阳性判定阈值:相应脑区内18F-DPA-714摄取强度高于健康对照平均SUVR加2个标准差。

临床应用与阅片要点

  • 18F-DPA-714 PET可作为MRI的补充手段用于自身免疫性脑炎的检测。
  • 阅片时可关注皮质区18F-DPA-714摄取增高,有癫痫发作的患者全皮质平均SUVR更高。

局限性

  • 18F-DPA-714 PET与常规MRI阳性检出率差异未达统计学显著(P=0.065)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Translocator protein (TSPO) PET has been used to visualize microglial activation in neuroinflammation and is a potential imaging tool for detecting autoimmune encephalitis (AIE). Purpose To compare the detection rate between TSPO radioligand fluorine 18 (18F) DPA-714 PET and conventional MRI and assess the relationship between 18F-DPA-714 uptake and clinical features in participants with AIE. Materials and Methods Healthy volunteers and patients with AIE were enrolled in this prospective study between December 2021 and April 2023. All participants underwent hybrid brain 18F-DPA-714 PET/MRI and antibody testing. Modified Rankin scale scoring and AIE-related symptoms were assessed in participants with AIE. Positive findings were defined as intensity of 18F-DPA-714 uptake above a threshold of the mean standardized uptake value ratio (SUVR) plus 2 SD inside the corresponding brain regions of healthy controls. The McNemar test was used to compare the positive detection rate between the two imaging modalities; the independent samples t test was used to compare continuous variables; and correlation with Bonferroni correction was used to assess the relationship between 18F-DPA-714 uptake and clinical features. Results A total of 25 participants with AIE (mean age, 39.24 years ± 19.03 [SD]) and 10 healthy controls (mean age, 28.70 years ± 5.14) were included. The positive detection rate of AIE was 72% (18 of 25) using 18F-DPA-714 PET compared to 44% (11 of 25) using conventional MRI, but the difference was not statistically significant (P = .065). Participants experiencing seizures exhibited significantly higher mean SUVR in the entire cortical region than those without seizures (1.23 ± 0.21 vs 1.15 ± 0.18; P = .003). Of the 13 participants with AIE who underwent follow-up PET/MRI, 11 (85%) demonstrated reduced uptake of 18F-DPA-714 accompanied by relief of symptoms after immunosuppressive treatment. Conclusion 18F-DPA-714 PET has potential value in supplementing MRI for AIE detection. Clinical trial registration no. NCT05293405 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Zaharchuk in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Zhang M, Meng H, Zhou Q, et al. Microglial Activation Imaging Using 18F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis. Radiology. 2024. PMID: 38441089. doi:10.1148/radiol.230397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。